Pathways to patients

How a customized stem cell therapy (a 351 biologic) moves from the lab to US patients.

  1. Preclinical and CMC foundation. Define the product: cell source, manufacturing process, potency assay, release specifications, and safety studies (tumorigenicity, biodistribution, as relevant).
  2. Early FDA engagement. CBER's Office of Therapeutic Products (OTP) offers INTERACT meetings for early, informal advice, and pre-IND meetings before you file.
  3. Investigational New Drug application (IND). Required before any human use. Academic investigators can hold their own INDs. FDA has 30 days to respond before a study may begin.
  4. Clinical trials (Phase 1 to 3). FDA's 2025 draft guidances encourage innovative designs for small populations and multi-site trials that pool data to support a BLA.
  5. Expedited programs. Regenerative Medicine Advanced Therapy (RMAT) designation is for cell and tissue therapies intended for serious or life-threatening conditions with preliminary clinical evidence. It sits alongside Fast Track, Breakthrough Therapy, Priority Review and Accelerated Approval.
  6. Biologics License Application (BLA). Approval covers the product and its manufacturing process and facilities.
  7. Post-approval. Long-term follow-up (especially for gene-modified cells), REMS where required, and post-approval manufacturing changes.

Access before approval

RouteWho it servesKey condition
Clinical trial (IND)Eligible enrolled patientsFDA-cleared protocol and IRB approval
Expanded access (single patient, intermediate-size, treatment IND)Patients with serious conditions and no comparable alternativeFDA authorization, IRB approval and the sponsor's agreement
Right to Try (federal law, 2018)Eligible patients with life-threatening conditionsInvestigational product has completed Phase 1, and the manufacturer agrees

Customized and point-of-care manufacturing

Truly individualized therapies (autologous, patient-specific or N-of-1) raise particular CMC questions: making the product at several sites, comparability between batches, and release testing on short timelines. FDA has discussed distributed and point-of-care manufacturing models publicly. Any such model still runs under an IND or a BLA, with quality controls at every site. There is no stand-alone "clinic license" route.

Tip: put manufacturing-site strategy (central, hub-and-spoke or point-of-care) on the table at your first INTERACT or pre-IND meeting. Changing it later is costly.